CDH1 and prostate carcinoma: To further elucidate the mechanisms underlying the anti-metastatic effects of Isorhamnetin, the expression of several epithelial−mesenchymal transition (EMT) marker (E-cadherin, vimentin, and N-cadherin) and androgen-independent prostate cancer-associated proteins (MMP-2 and MMP-9) were assessed by Western blot analysis.